Tsinnarizin

When ATH:
N07CA02

Characteristic.

Derivative difenilpiperazina.

Pharmacological action.
Vasodilator, improving brain blood circulation, improves peripheral circulation.

Application.

Cerebrovascular accidents: atherosclerosis of the brain, ischemic stroke, post-hemorrhagic stroke and traumatic brain injury, encephalopathy; dizziness, noise in ears, depression and irritability, quick mental fatigue, migraine, senilynaya dementia, decline and memory loss, thought disorder and inability to concentrate; treatment and prevention of disorders of the peripheral circulation (Raynaud's disease, atherosclerosis, thromboangiitis obliterans (Buerger's disease), diabetic angiopathy, acrocyanosis, intermittent claudication, trophic and varicose ulcers, paresthesia, cold extremities); supportive care for symptoms labyrinth disorders, including dizziness, noise in ears (tinnitus), nistagmo, nausea and vomiting; Prevention kinetoses.

Contraindications.

Hypersensitivity, lactation.

Restrictions apply.

Pregnancy, Parkinson's disease.

Pregnancy and breast-feeding.

When pregnancy is possible, if the effect of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.

Side effects.

From the nervous system and sensory organs: drowsiness, fatiguability, headache.

From the digestive tract: dry mouth, dyspepsia, epigastric pain, cholestatic jaundice.

For the skin: increased perspiration, manifestations of lupus erythematosus or lichen planus.

Other: allergic skin reactions, weight gain; very rarely - tremor of the limbs, increased muscle tone.

Cooperation.

Chemical incompatibility is not known.

It enhances the effect of alcohol, sedatives, antihypertensive and vasodilator drugs. It enhances the effect of nootropics. It reduces the effect of agents for the treatment of arterial hypotension.

Overdose.

Treatment: gastric lavage, administration of activated charcoal, simptomaticheskaya therapy. No specific antidote.

Dosing and Administration.

Inside, preferably after meals. Cerebrovascular accident: 25-50 mg 3 once a day, the peripheral blood circulation: 50–75 mg 3 once a day, disequilibrium: by 25 mg 3 once a day, Prevention kinetoses: adults - 25 mg for 30 minutes before the trip, if necessary, repeated at 6 h up to the maximum recommended dose - 225 mg. Children appoint half the adult dose. With high sensitivity Cinnarizinum treatment begins with 1/2 dose, increasing it gradually.

Precautions.

Be wary of during the drivers of vehicles and people, skills relate to the high concentration of attention (possible drowsiness, especially at the beginning of treatment). Patients with Parkinson's disease may be appointed only if the effect of therapy outweighs the risk of worsening of the underlying disease. With prolonged use monitoring of liver function is recommended, kidney and peripheral blood.

Cooperation